The EHBP1L1 Knockout NCI-H1975 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population designed for the targeted disruption of the EHBP1L1 gene in the human NCI-H1975 non-small cell lung cancer (NSCLC) cell line. This polyclonal pool contains a heterogeneous mixture of NCI-H1975 cells carrying diverse CRISPR/Cas9-mediated gene disruptions at the EHBP1L1 locus, providing a loss-of-function model suitable for studying the role of EHBP1L1 in endocytosis and cancer signaling. As a polyclonal knockout population, this reagent avoids biases associated with clonal selection and represents a broadly applicable tool for functional genomics in EGFR-mutant lung adenocarcinoma research. The cells are supplied as a living culture and can be expanded under standard conditions for downstream applications.
The NCI-H1975 host cell line is a well-characterized epithelial lung adenocarcinoma model derived from a non-smoking female patient. It harbors heterozygous L858R and T790M mutations in the epidermal growth factor receptor (EGFR) kinase domain, which confer constitutive activation and resistance to first-generation tyrosine kinase inhibitors (TKIs) while retaining sensitivity to third-generation agents such as osimertinib. NCI-H1975 cells are widely employed as a clinically relevant system for investigating EGFR-driven oncogenic signaling, acquired drug resistance, and the tumor biology of NSCLC. Their adherent growth properties and well-documented molecular landscape make them an ideal background for dissecting the contributions of endocytic adaptors to EGFR-mediated malignancy.
EHBP1L1 (EH domain-binding protein 1-like 1) encodes an adaptor protein that bridges EH domain-containing proteins and BAR domain-containing proteins, thereby coordinating clathrin-mediated endocytosis with actin cytoskeleton remodeling. Mechanistically, EHBP1L1 is recruited to endocytic sites through interactions with Eps15 and Eps15R, which are activated downstream of EGFR ligand stimulation. It then engages BAR domain proteins such as Bin1 to induce membrane curvature and facilitate vesicle scission, while also associating with actin regulatory factors to promote actin polymerization at endocytic pits. This integration of membrane deformation and cytoskeletal dynamics is essential for efficient EGFR internalization and subsequent recycling to the plasma membrane. In the EGFR signaling network, EHBP1L1 functions downstream of EGFR activation and Eps15/Eps15R, and its activity influences Rab GTPase-mediated endosomal sorting, ultimately modulating the duration and intensity of downstream ERK and AKT signals. Disruption of EHBP1L1 therefore impairs the coupling of endocytic trafficking to signal transduction, potentially altering the balance of EGFR degradation versus recycling.
In the context of NCI-H1975 cells, knockout of EHBP1L1 is expected to perturb EGFR trafficking dynamics, as these cells rely heavily on sustained EGFR surface expression for maintaining oncogenic signaling through the L858R/T790M mutant receptor. By disrupting the adaptor function that supports clathrin-mediated EGFR endocytosis and recycling, EHBP1L1 disruption may lead to reduced EGFR protein levels at the cell surface, attenuated downstream signaling, and decreased cell proliferation under EGFR-driven selection. Furthermore, because EHBP1L1 directly impacts actin cytoskeleton organization, its loss could also compromise cell migration and invasion, processes intimately linked to cancer metastasis. This cell model thus provides a unique platform to dissect how endocytic machinery contributes to EGFR-TKI sensitivity and the development of resistance in NSCLC, revealing potential vulnerabilities that could be exploited therapeutically.
This EHBP1L1 knockout polyclonal cell population is suitable for a wide range of experimental applications in cancer cell biology and drug discovery. Researchers can employ western blotting to assess EGFR and downstream effector phosphorylation (e.g., ERK, AKT), monitor EGFR internalization and recycling kinetics using fluorescent ligand-binding or antibody-feeding assays, and visualize endocytic compartments by immunofluorescence staining for markers such as EEA1 or LAMP1. Cell migration and invasion can be quantified in transwell or scratch-wound assays, while proliferation studies under escalating doses of EGFR inhibitors (e.g., osimertinib) can evaluate the contribution of EHBP1L1 to therapeutic response. Co-immunoprecipitation and pull-down experiments enable validation of disrupted protein interactions with Eps15, Bin1, or actin. By combining these approaches, investigators can delineate the role of EHBP1L1 in EGFR trafficking, actin dynamics, and NSCLC progression. For technical inquiries, please contact Ascent Research.
